Samotolisib

Other Medications

Description

Samotolisib is an investigational drug currently being studied in clinical trials. It is being investigated for certain types of cancer, including some advanced solid tumors in pediatric patients. The trials are designed to see if targeting specific genetic changes (mutations) in a patient's tumor with this drug can help treat the cancer. It is being studied in combination with other targeted therapies. The specific role of samotolisib in colorectal cancer is still under investigation, and it is not yet an approved treatment for this disease.

Mechanism of Action

Samotolisib is being studied as a targeted therapy. It targets a specific protein involved in cell signaling pathways that can contribute to tumor growth and survival. The specific protein target is being characterized in clinical trials. It is designed to block the activity of this protein, potentially slowing or stopping cancer cell growth.

Side Effects

As an investigational drug The full range of side effects for samotolisib is still being evaluated in ongoing clinical trials. Side effects observed in trials for related drugs or in early trials for samotolisib may include fatigue Nausea Diarrhea Rash And other potential toxicities. The specific side effects and their frequency are still being determined.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03155620 Phase 2
Active, not recruiting
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
United States, Australia, Canada, Puerto Rico